secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001093557-25-000111
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DexCom Q1 revenue $1.04B (+12% YoY); guides FY25 gross margin ~62% (down); announces $750M buyback
--------------------------------------------------------------------------------

- GAAP net income $105.4M ($0.27 diluted EPS) vs $146.4M ($0.36) YoY; non-GAAP EPS $0.32 flat.
- Revenue $1.036B (+12% reported, +14% organic); US +15%, intl +7% (organic +12%).
- FY25 guidance: revenue $4.6B (+14%), non-GAAP gross margin ~62% (cut from prior), op margin ~21%, EBITDA margin ~30%.
- Board authorized $750M share repurchase program through June 30, 2026.
- Post-quarter FDA clearance for G7 15-day system; expanded PBM coverage and Stelo on Amazon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355725000111/0001093557-25-000111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355725000111/dxcm-20250501.htm
  HTML page:      https://secwatch.observer/filing/0001093557-25-000111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer